GöttinGen 7.- 9. Februar - Programm - Jahrestagung des Deutschen Pankreasclubs eV
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
Programm
© fotobeam.de l Fotolia.com
DPC
39. Jahrestagung des
Deutschen Pankreasclubs e. V.
7.– 9. Februar
Göttingen
www.dpc-kongress.de
WIR ENGAGIEREN UNS FÜR
SCHWERWIEGENDE UND
SELTENE ERKRANKUNGEN MIT
DER FORSCHUNGSKOMPETENZ
ANTISENSE-TECHNOLOGIE
2
DE-AKCEA-0009-V01-2018-10
INHALTSVERZEICHNIS
Organisation und Impressum . ............................................................................................... 4
Grußwort der Tagungsleitung ................................................................................................ 5
Workshops I Donnerstag, 7. Februar ................................................................................... 6
Wissenschaftliches Programm
Donnerstag, 7. Februar ................................................................................................. 7
Freitag, 8. Februar ......................................................................................................... 9
Samstag, 9. Februar . ..................................................................................................... 14
Posterpräsentationen
Donnerstag, 7. Februar ................................................................................................. 17
Freitag, 8. Februar ......................................................................................................... 22
Abend- und Rahmenprogramm ............................................................................................. 27
Industriegestützte Sessions.................................................................................................... 28
Sponsoren und Medienkooperation ..................................................................................... 32
Aussteller ................................................................................................................................ 34
Raum- und Ausstellerplan ...................................................................................................... 35
Allgemeine Informationen ..................................................................................................... 36
Index Referenten, Autoren und Vorsitzende . ....................................................................... 37
3
ORGANISATION UND IMPRESSUM Tagungsort und Termin Tagungs- und Veranstaltungshaus Alte Mensa Göttingen Wilhelmsplatz 3 I 37073 Göttingen 7.–9. Februar 2019 Tagungshomepage www.dpc-kongress.de Veranstalter Deutscher Pankreasclub e. V. www.pankreasclub.de Wissenschaftliche Leitung PD Dr. Dr. med. Albrecht Neeße Klinik für Gastroenterologie und gastrointestinale Onkologie Universitätsmedizin Göttingen Tagungsorganisation Conventus Congressmanagement & Marketing GmbH Ariane Kärger/Carolin Hofmann Carl-Pulfrich-Straße 1 I 07745 Jena Tel. +49 3641 31 16-325/-378 dpc@conventus.de I www.conventus.de Programmerstellung Satz krea.tif-studio UG (haftungsbeschränkt) Druck printworld.com GmbH Auflage 300 Redaktionsschluss 18. Januar 2019 4
GRUSSWORT DER TAGUNGSLEITUNG
Liebe Kolleginnen und Kollegen,
ich freue mich, Sie im Jahr 2019 zur 39. Jahrestagung des Deutschen Pankreasclubs e. V. nach
Göttingen, in die Stadt, die Wissen schafft, einzuladen.
Das Leitbild 2019 „Pankreatologie im Zeitalter der Viszeralmedizin: Translation und Vernetzung“
soll als Basis für den interdisziplinären wissenschaftlichen und klinischen Austausch dienen.
Nationale und internationale renommierte Experten werden Sie aktuell und praxisnah auf
den neuesten Stand der Pankreasforschung und klinischen Versorgung bringen. Zusätzlich
bieten wir auch 2019 wieder die Möglichkeit, sich am Donnerstagvormittag in klinisch und
translational orientierten Veranstaltungen und Workshops praxisrelevantes Wissen anzueignen.
Ich freue mich auf eine lebhafte Tagung, viele inspirierende Akzente und facettenreiche
Diskussionen.
Herzliche Grüße,
Ihr
Albrecht Neeße
© di
s p l ay
i nte r may a l f
o to lia.c o m
5
WORKSHOPS I DONNERSTAG, 7. FEBRUAR
WORKSHOPS I THURSDAY, 7 FEBRUARY
All workshops will take place at the University Hospital Göttingen (Robert-Koch-Straße 40).
09:30–12:30 Workshop 1 l Diagnostische und interventionelle Sonographie in der
Pankreatologie (B-Bild, CEUS, EUS, EUS-FNA/FNB) mit Live Demo
Room Department of Gastroenterology and Gastrointestinal Oncology
B-Bild Sonographie der Pankreatologie
V. Keim (Leipzig)
CEUS
G. Petzold (Göttingen)
Endosonographie der Pankreatologie
A. Arlt (Kiel)
Live Demo
S. Kunsch (Göttingen)
09:30–12:30 Workshop 2 l Syngenic orthotopic PDAC cell transplantation
Room Laboratories Gastroenterology and Gastrointestinal Oncology
Theory and Hands-on Training
E. Hessmann (Göttingen)
09:30–12:30 Workshop 3 l High-resolution ultrasound and preclinical trial design using
orthotopic and genetically engineered model systems
Room Laboratories Gastroenterology and Gastrointestinal Oncology
Theory and Hands-on Training
R. Goetze (Göttingen)
08:30–12:30 Workshop 4 l Präparierkurs Pankreaskopfresektion
Room Anatomy of the University Hospital Göttingen
Hands-on Training
J. Gaedcke (Göttingen)
10:30–12:30 PASS 1-2 Trials Meeting
Room Lecture Theater 552
6WISSENSCHAFTLICHES PROGRAMM I DONNERSTAG, 7. FEBRUAR
SCIENTIFIC PROGRAMME I THURSDAY, 7 FEBRUARY
13:30–14:00 Welcome session
Room Adam-von-Trott-Saal
Welcome note of the conference chair
A. Neeße (Göttingen)
Welcome note of the DGIM secretary general
U. R. Fölsch (Kiel)
14:00–15:30 Session 1 I Clinical and translational pancreatology
Room Adam-von-Trott-Saal
Chairs U. Wittel (Freiburg), I. E. Demir (Munich)
14:00 Keynote I Walter Halangk memorial lecture
The German Pancreas Club will honor the memory of Walter Halangk
(longtime secretary of the DPC) with a Walter Halangk memorial lecture by
J. Mayerle (Munich)
14:18 Neoadjuvant treatment for locally advanced pancreatic cancer – prognostic
factors of survival
U. Klaiber, E. S. Schnaidt, U. Heger, M. Sachsenmaier, U. Hinz, O. Strobel
M. W. Büchler, T. Hackert (Heidelberg)
14:26 Targeting DNA damage response by establishing synergistic therapeutic
routes in DDR deficient pancreatic cancer
L. Perkhofer, J. Gout, M. Morawe, F. Arnold, P.-O. Frappart, A. Kleger (Ulm)
14:34 Theranostic targeting of pancreatic cancer cells using CD44 variant
6-specific aptamers
J. Peterhansl, U. M. Mahajan, E. Osterode, K. Lauber, Qi. Li, I. Regel
J. Mayerle (Munich)
14:42 Keynote I Metabolism in pancreatic diseases – To fast or not to fast!
H. Algül (Munich)
15:00 Prognostic impact of tumor-infiltrating leukocytes on survival of patients
with primary resected pancreatic cancer
R. C. Miksch, M. Weniger, S. Ormanns, J. Werner, A. V. Bazhin
J. G. D’Haese (Munich)
15:08 P90-RSK as a synthetic lethal target in pancreatic cancer – molecular
characterisation and therapeutic inhibition
J. Riedel (Halle a. d. Saale), N. Milosevic (Gießen), J. von Kries
M. Nazare (Berlin), H. Griesmann, P. Michl (Halle a. d. Saale)
15:16 Locally advanced and borderline-resectable pancreatic adenocarcinoma:
neoadjuvant FOLFIRINOX as part of a multimodal strategy with curative
intention
S. Acciuffi, J. Omari, R. Drewes, D. Jechorek, R. Croner, H. Ptok (Magdeburg)
7WISSENSCHAFTLICHES PROGRAMM I DONNERSTAG, 7. FEBRUAR
SCIENTIFIC PROGRAMME I THURSDAY, 7 FEBRUARY
15:45–17:15 Poster sessions 1–3 (please see pages 17–21)
17:30–19:00 Session 2 I Pancreatitis and pancreatic cancer – clinical and basic science
Room Adam-von-Trott-Saal
Chairs R. Jaster (Rostock), G. von Figura (Munich)
17:30 Keynote I Autoimmune pancreatitis and the UEG guideline effort
J. Rosendahl
17:48 Clinical significance of immunosuppressive therapy with tacrolimus in
IgG4-related autoimmune pancreatitis – our experience in a cohort of 71
patients
A. Kahraman, M. Büchter, G. Gerken (Essen)
17:56 Foxp3+/CD25+ regulatory T cells influence the T-cell response and systemic
inflammation in a mouse model of acute pancreatitis
J. Glaubitz, A. Wilden, C. van den Brandt, F. U. Weiß (Greifswald)
J. Mayerle (Munich), M. M. Lerch, M. Sendler (Greifswald)
18:04 The Axon Guidance Receptor ROBO3 mediated transcriptional regulation
links to pancreatic cancer plasticity
N. Krebs, S. Önder, X. Xu, J. M. Güntner, M. Tu, V. Ellenrieder
S. K. Singh (Göttingen)
18:12 PPDPF impacts human pancreatic progenitor cell formation
M. Breunig, M. Hohwieler, N. Zhang (Ulm), J. Glöckner (Tübingen)
T. Seufferlein (Ulm), S. Liebau (Tübingen), A. Kleger (Ulm)
18:20 Oncogenic network analysis of ALDH1A3-positive pancreatic ductal
adenocarcinoma
M. Shi, J. Cao, J. Akkan, N. Maeritz, G. O. Ceyhan, H. Friess (Munich)
C. Michalski, J. Kleeff (Halle a. d. Saale), B. Kong (Munich)
18:28 Epigenetic modifications distinguish between the classical and basal
pancreatic cancer subtype
S. Pichlmeier, A. Kirmayr, S. Benitz, U. M. Mahajan, L. Fahr (Munich)
C. Michalski, J. Kleeff (Halle a. d. Saale), J. G. D’Haese, J. Mayerle
I. Regel (Munich)
18:36 Keynote I Why surgical treatment for chronic pancreatitis patients is so
important
G. O. Ceyhan (Istanbul/TR)
19:30–21:30 Get together (please see page 27)
8WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR
SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY
08:30–10:00 Session 3 I Pancreatic surgery
Room Adam-von-Trott-Saal
Chairs J. Kleeff (Halle a. d. Saale), J. Gaedcke (Göttingen)
08:30 Keynote I Opportunities and limits of minimally invasive pancreatic
surgery
T. Keck (Lübeck)
08:48 Long-term overall survival and prognostic factors after
pancreatoduodenectomy for ampullary cancer – analysis of a large
multicenter cohort of more than 200 patients
L. Bolm, K. Ohrner (Lübeck), F. Rückert (Mannheim)
B. M. Rau (Neustadt i. d. Oberpfalz), E. Petrova, D. Bausch (Lübeck)
J. Weitz (Dresden), T. Keck, U. Wellner (Lübeck), M. Distler (Dresden)
08:56 An R0-resectable, genetically engineered mouse model of pancreatic
cancer mimics the response to neoadjuvant chemotherapy in human PDAC
C. Mota-Reyes (Munich), B. Mundt, J. Brooks (Hannover), B. Konukiewitz
A. Muckenhuber, S. Teller, W. Weichert (Munich), F. Kühnel (Hannover)
H. Friess, G. O. Ceyhan, I. E. Demir (Munich)
09:04 Volume outcome relationship in pancreatic surgery – effects of hospital and
surgeon volume on mortality and postoperative pancreatic fistula
S. Acciuffi, H. Ptok (Magdeburg), I. Gastinger (Cottbus)
R. Croner (Magdeburg), H. Dralle (Essen)
09:12 Keynote I Career options for young surgeons – Clinic, science or both?
C. Michalski (Halle a. d. Saale)
09:30 Trans-parenchymatous sutures cause substantial and persistent
inflammation in mouse pancreas
C. Kühlbrey, A. Zabadne, U. Wittel (Freiburg)
09:38 Patterns of recurrence after resection of pancreatic ductal adenocarcinoma
in the ESPAC-4 Trial
J. Neoptolemos, T. Hackert, C. Tjaden (Heidelberg), R. Jones, E. Psarelli
R. Jackson, P. Ghaneh, C. Halloran, D. Palmer (Liverpool/GB), O. Strobel
M. Buchler (Heidelberg)
09:46 Activated stroma index in neoadjuvantly treated patients with pancreatic
ductal adenocarcinoma
A. Martens, U. Heger, B. Walter, H. Sun, S. Roth (Heidelberg)
C. Michalski (Halle a. d. Saale), M. W. Büchler, T. Hackert (Heidelberg)
9WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR
SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY
10:15–12:00 Session 4 I Clinical trials and novel therapies
Room Adam-von-Trott-Saal
Chairs V. Ellenrieder (Göttingen), C. Bruns (Cologne)
10:15 Keynote I Immuno-oncology – the basics and future perspectives
H. Flach (Munich)
10:45 In-depth molecular characterisation of pancreatic ductal adenocarcinoma
based on patient-derived tumor organoids
S. Le Blanc, T. Bauer (Heidelberg), N. Ishaque (Berlin), S. Schuth, A.-K. König
M. Volkmar, C.-S. Leonhardt, J. Jabs, U. Toprak, M. Schenk, N. Giese
R. Offringa, C. Conrad, M. W. Büchler, M. Schlesner (Heidelberg)
R. Eils (Heidelberg, Berlin), O. Strobel (Heidelberg)
10:53 Keynote I Future clinical trial concepts in PDAC
J. Siveke (Essen)
11:23 Reliability of determining the resectability of locally progressed pancreatic
ductaladenocarcinomas – results from the CONKO-007 multicenter
randomised controlled trial (EudraCT:2009-014476-21)
U. Wittel (Freiburg), H. Golcher, R. Grützmann (Erlangen)
W. Bechstein (Frankfurt), O. Belyaev, W. Uhl (Bochum)
M. Ghadimi (Göttingen), U. Hopt (Freiburg), A. Pirkl, D. Lubgan
W. Hohenberger (Erlangen), H. Oettle (Friedrichshafen), R. Fietkau (Erlangen)
11:31 Comparative characterisation and epigenetic/metabolic targeting of
primary 2D and 3D cultured PDAC cells
S.-T. Liffers, S. Mergener, A. Winkelkotte, M. Trajkovic-Arsic, S. S. Lueong
J. Forster (Essen), S. Hahn (Bochum), J. Siveke (Essen)
11:39 Keynote l PASS1/2 trial
J. Neoptolemos (Heidelberg)
11:47–12:30 Coffee break and visit of the industrial exhibition
12:00–12:15 AG Pankreas Meeting
12:30–14:00 Poster sessions 4–6 (please see pages 22–26)
12:45–13:45 Student meeting Professor Ghadimi
10WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR
SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY
14:00–15:00 Session 5 I Endoscopy
Room Adam-von-Trott-Saal
Chairs A. Hoffmeister (Leipzig), A. Arlt (Kiel)
14:00 Value of EUS guided drainage in the management of postoperative
pancreatic fistulas and fluid collections – a retrospective multi center analysis
M. Distler (Dresden), C. Jürgensen (Berlin), A. Arlt (Kiel)
S. Brückner (Dresden), M. Ellrichmann (Kiel), K. Matthes (Dresden)
M. Ludwig (Berlin), S. Sulk, L. Romberg, S. Zeissig (Dresden)
C. Schafmayer, S. Hinz (Kiel), T. Welsch (Dresden), M. Bahra (Berlin)
H. Aselmann (Kiel), J. Weitz (Dresden), F. Klein (Berlin), T. Becker (Kiel)
J. Hampe (Dresden)
14:08 Endoscopic necrectomy of the infected WON – development of an
effective therapy algorithm on the basis of a monocentric population
K. Jäger, F. Füldner (Gera), F. Meyer (Magdeburg), U. Will (Gera)
14:16 Keynote l Current standards and controversies in the endoscopic
treatment of pancreatic necroses
J. Hampe (Dresden)
14:34 Comparative characterisation of postoperative pancreatic fistula according
to the 2005 and 2016 definitions of the International Study Group for
Pancreatic Surgery
E. Petrova, L. Bolm, H. Lapshyn, C. Busch, L. Frohneberg, S. Deichmann
K. C. Honselmann, D. Bausch, T. Keck, U. Wellner (Lübeck)
14:42 Keynote l EUS – Interventionen bei benignen und malignen Erkrankungen
des Pankreas – Möglichkeiten und Grenzen
U. Will (Gera)
14:51–15:15 Coffee break and visit of the industrial exhibition
11WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR
SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY
15:15–17:00 Session 6 I Pancreatic cancer – clinical and translational research
Room Adam-von-Trott-Saal
Chairs M. Ghadimi (Göttingen), R. Schmid (Munich)
15:15 Keynote l Medical therapy of pancreatic ductal adenocarcinomas
A. König (Göttingen)
Oxford discussion l surgery for oligo-metastatic pancreatic cancer patients
15:36
1. Opening statement pro vs. contra surgery for oligometastatic PDAC
5min for each speaker
2. Question time for both chairs – 3min for each speaker
3. Exchange of questions between the speakers (3–5min)
4. Question time for the audience (max 5min)
5. Final statements from the speakers – 2min for each speaker
6. Audience vote
S. Kersting (Erlangen), T. Seufferlein (Ulm)
16:06 The role of GSK3β in chromatin plasticity and DNA damage repair mechanisms
G. E. Schmidt, K. Reutlinger, L. Augustin, M. C. Hasselluhn, A. Tirilomi
E. Hessmann, S. A. Johnsen, V. Ellenrieder (Göttingen)
16:14 The interaction of tumor and stroma via the IL-17B/RB axis affects
metastatic potential of pancreatic ductal adenocarcinoma
J. Li, Q. Sun, J. Zhao, Z. Wang, J. Qin, X. Wu, C. Bruns, Yu. Zhao
F. Popp (Cologne)
16:22 The clinical relevance of a novel matrisome signature in PDAC
K. C. Honselmann (Lübeck; Boston, MA/US), Dan. Birnbaum (Marseille/FR)
S. Begg, P. Finetti, Dav. Birnbaum, F. Bertucci, D. Ting, E. Tai, C. Monsalve
M. Mino- Kenudson, K. Lillemoe, C. Fernandez-del Castillo, A. Warshaw
A. Liss (Boston, MA/US)
16:30 Identification of superior combinatorial PDA therapies involving cytostatic
agents and immunostimulatory antibodies in a clinically relevant mouse
model
D. Baumann, J. Mochayedi, T. Hägele, J. Drebant, C. Vent, I. Poschke
M. Volkmar, R. Offringa (Heidelberg)
16:38 Tumor exosomes modulate progression of PDAC and distant metastasis
S. Polaschek, T. Eiseler, T. Seufferlein (Ulm)
12WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR
SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY
16:46 Utilising patient-derived organoids from endoscopic fine needle aspiration
as a diagnostic tool and research platform for personalised medicine in
pancreatic ductal adenocarcinoma
Z. Dantes, H.-Y. Yen, K. Steiger, A. Muckenhuber, N. Pfarr, C. Winter
T. Engleitner, S. Lange, R. Öllinger, I. Heid, K. Shi, K. Peschke, K. Feldmann
C. Lubeseder-Martellato, M. Martignoni, G. O. Ceyhan, H. Friess, A. Herner
L. Liotta, M. Treiber, G. von Figura, M. Abdelhafez, P. Klare
C. Schlag (Munich), J. Siveke (Essen), R. Braren, W. Weichert, D. Saur
R. Schmid, R. Rad, G. Schneider, M. Reichert (Munich)
16:54–17:15 Coffee break and visit of the industrial exhibition
17:15–18:30 Session 7 I Acute and chronic pancreatitis
Room Adam-von-Trott-Saal
Chairs J. Rosendahl (Halle a. d. Saale), J. Mayerle (Munich)
17:15 Myeloid derived suppressor cell (MDSCs) differentiation during acute
pancreatitis regulates the systemic immune response
A. Wilden, J. Glaubitz, J. Golchert, G. Homuth, F. U. Weiß (Greifswald)
J. Mayerle (Munich), M. Sendler, M. M. Lerch (Greifswald)
17:23 Mast cell stabilisers ameliorate pain in experimental chronic pancreatitis
S. Klauss, S. Schorn, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich)
17:31 Keynote I Pancreatitis in patients with lipid disorders
M. M. Lerch (Greifswald)
18:01 Gender-dependent mechanisms of autophagy in the transition of acute to
chronic pancreatitis
K. Diakopoulos, A. Berninger, M. Kowalska, K. Görgülü, M. Lesina, J. Ai
A.-F. Karpathaki, D. Kabacaoglu, K. J. Ciecielski, E. Kaya-Aksoy, R. Schmid
H. Algül (Munich)
18:09 Pancreatic autophagy attenuates endotoxin-induced pancreatic injury
L. Xia, T. Hackert, F. Fortunato (Heidelberg)
18:17 Absence of LMP7 immunoproteasome subunit leads to delayed organ
recovery after acute pancreatitis
L. De Freitas Chama, F. U. Weiß, F. Ebstein, E. Krüger, M. M. Lerch
M. Sendler (Greifswald)
18:30–19:30 General assembly
Room Adam-von-Trott-Saal
20:00 Conference dinner and award ceremony at the Freizeit In Hotel
(please see page 27)
13WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR
SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY
08:30–09:45 Session 8 I Neuroendocrine tumors
Room Adam-von-Trott-Saal
Chairs J. Werner (Munich), S. Krug (Halle a. d. Saale)
08:30 C-reactive protein (CRP) is associated with poor prognosis by promoting
growth signaling pathway activation in pancreatic neuroendocrine neo
plasms
S. Schimmack, Y. Yang, F. Bergmann, K. Felix, T. Hackert
O. Strobel (Heidelberg)
08:38 Cause of death in patients with pancreatic neuroendocrine neoplasms
(pNEN) – analysis of 6465 cases in the surveillance, epidemiology, and end
results (SEER) database
L. P. Breitling, A. Rinke, T. Gress (Marburg)
08:46 Keynote I New German S2K guideline for neuroendocrine tumours:
„What is new for PNENs?”
T. Gress (Marburg)
09:04 Primary pancreatic tumor resection results in superior overall and
prolonged progression free survival after peptide receptor radionuclide
therapy in advanced neuroendocrine neoplasms
D. Kämmerer (Bad Berka), M. Twrznik (Mühlhausen), D. Hörsch
R. P. Baum, M. Hommann (Bad Berka)
09:12 Keynote l Surgery for pancreatic neuroendocrine tumors – which
operation for which patient
O. Strobel (Heidelberg)
09:30 Mir-132 controls beta cell proliferation and survival in mouse
model through the PTEN/AKT/FOXO3 signaling
S. Kersting (Erlangen), H. Mziaut (Dresden), M. Solimena (Erlangen, Dresden)
09:38 Pathology has the last word – pancreatic fibrosis is a better parameter for
prediction of pancreatic fistula than texture – a retrospective analysis from
the RECOPANC Trial
E. Petrova (Lübeck), S. Timme, M. Werner (Freiburg), T. Keck (Lübeck)
P. Bronsert (Freiburg), U. Wellner (Lübeck)
09:46–10:00 Coffee break and visit of the industrial exhibition
14WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR
SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY
10:00–11:45 Session 9 l Tumor microenvironment, stem cells and epigenetics
Room Adam-von-Trott-Saal
Chairs I. Regel (Munich), E. Hessmann (Göttingen)
10:00 Keynote I Pancreatic cancer
D. Tuveson (Cold Spring Harborg, NY/US)
10:30 Immune infiltration patterns in genetically engineered mouse models of
pancreatic cancer largely depend on the age and only partly reflect the
human disease
O. Safak, I. E. Demir, S. Wang, I. Gürcinar, B. Yilmaz, C. Mota-Reyes, H. Friess
G. O. Ceyhan (Munich)
10:38 Characterisation of p53-dependent oncogenic EZH2-activity in pancreatic
cancer
L. Versemann, H. Witte, W. Kopp, J. Spitalieri, X. Xu, V. Ellenrieder
E. Hessmann (Göttingen)
10:46 Bulk and single-cell T-cell receptor and transcriptome profiling reveals
significant phenotypic, spatial and temporal heterogeneity in the
tumor-infiltrating lymphocyte repertoire of pancreatic cancer and
melanoma patients
I. Poschke, C. L. Tan, I. Heras-Murillo, K. Lindner, A. Rodrizuez-Ehrenfried
L. Appel, K. König, M. W. Büchler (Heidelberg), U. Sahin (Mainz), J. Hassel
O. Strobel (Heidelberg), M. Flossdorf (Munich), R. Offringa (Heidelberg)
10:54 Keynote I Stem cells and their application in pancreatic cancer research
A. Kleger (Ulm)
11:12 Site-specific angiogenesis may promote isolated pulmonary metastasis in
pancreatic cancer
T. Krauss, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich)
11:20 Analysing molecular regulation in pancreatic cancer based on (i) the
interaction of tumour and its peritumoral tissue, (ii) intercellular
communication within the tumour microenvironment and (iii) intracellular
methylation changes in tumour-relevant gene promoters
J. D. Hoheisel, M. S. S. Alhamdani (Heidelberg), E. A. Moskalev (Erlangen)
A. S. Bauer, Ye. Wu, N. Giese, T. Hackert, O. Strobel
M. W. Büchler (Heidelberg)
11:28 Identification of DNA mutations in pancreatic stellate cells
V. Böker, J. Kleeff (Halle a. d. Saale)
15WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR
SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY
12:00–13:30 Session 10 I Cystic lesions and precursor lesions of the pancreas
Room Adam-von-Trott-Saal
Chairs I. Esposito (Düsseldorf), D. Bausch (Lübeck)
12:00 A coherent roadmap to generate pancreatic duct-like cells from human
pluripotent stem cells to model plasticity and dysplasia in the pancreas
M. Hohwieler, M. Breunig, J. Merkle, S. Heller, T. Seufferlein, P.-O. Frappart
A. Kleger (Ulm)
12:08 mTORC1 and mTORC2 converge at the Arp 2/3 complex-mediated actin
cytoskeleton regulation in promoting ADM formation
Ya. Zhao, V. Tissen, L. Chang, J. G. D’Haese, S. Raulefs, J. Qin, J. Akkan, Y. Yu
Z. Zhang, J. Cao, S. Benitz, G. O. Ceyhan, H. Friess, B. Kong (Munich)
12:24 Keynote I Cystic lesions of the pancreas – clinical impact and molecular
insights
P. Michl (Halle a. d. Saale)
12:16 Sensitive and specific identification of mutanome-encoded T-cell epitopes
in PDAC on the basis of xenograft NGS data using a hybrid reference
genome
M. Volkmar (Heidelberg), D. Hoser (Berlin), C. Lauenstein, J. Rebmann
A. Hotz-Wagenblatt, J. Rieger, I. Poschke, M. Sprick, A. Trumpp
M. Büchler, O. Strobel (Heidelberg), G. Willimsky (Berlin)
R. Offringa (Heidelberg)
12:42 Ablation of Hnf1b in adult pancreatic acinar cells inhibits precancerous
lesions in mice
S. Zhong, A. Hidalgo Sastre, G. von Figura (Munich)
12:50 Functional and mechanistic implications of ARID1A-deficiency in pancreatic
metaplasia and PDAC initiation
Z. Zhang, W. Kopp, H. Bohnenberger, Xin. Wang, F. Hamdan, M. Sen
L. Aperdannier, S. A. Johnsen, E. Hessmann (Göttingen)
12:58 Effects of RSK3 modulation on autophagy and metabolism in pancreatic
cancer
B. B. K. Dinh, J. Riedel, H. Griesmann, P. Michl (Halle a. d. Saale)
13:06 Keynote I Pancreatic cyst surgery – Oncological, parenchyma sparing,
minimally invasive?
T. Hackert (Heidelberg)
13:30–14:00 Farewell and invitation to Halle
Room Adam-von-Trott-Saal
C. Michalski, S. Krug (Halle a. d. Saale)
16POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR
POSTER SESSIONS I THURSDAY, 7. FEBRUARY
15:45–17:15 Poster session 1 I Tumor biology and therapy
Room Terminal 1
Chairs L. Perkhofer (Ulm), R. Schulz-Heddergott (Göttingen)
P 01 Crosstalk between IGF2BP RNA-binding proteins and epigenetic regulators
in pancreatic neuroendocrine tumors
F. Sperling, L. Nietfeld, S. Hüttelmaier, P. Michl, H. Griesmann (Halle a. d. Saale)
P 02 Role of PAI-1 in cell-proliferation and metastasis of pancreatic carcinoma cells
Q. Wang, A. Rech, F. Seyfried, E. Birgin, F. Rückert, P. Pallavi (Mannheim)
P 03 Evaluation of the effect of cancer-associated fibroblasts on the response of
pancreatic cancer organoids to drug treatment in a 3D coculture model
S. Schuth, S. Le Blanc, J. Jabs, M. Schenk, N. Giese, R. Offringa, C. Conrad
O. Strobel (Heidelberg)
P 04 Pancreatic cancer cells access nerves via TGFbeta1-mediated
transdifferentiation of perineural epithelial cells into mesenchymal-like cells
I. E. Demir, U. Bourquain, S. Teller, E. Krohmer, D. Saur, H. Friess
G. O. Ceyhan (Munich)
P 05 Vitamin D modulates proliferation, migration and activation of pancreatic
stellate cells and tumor-stroma crosstalk
Ya. Wu, Qu. Li, M. Weniger, M. Ilmer, J. Werner, A. V. Bazhin
J. G. D’Haese (Munich)
P 06 Intratumoral T cell dysfunction in a murine model of pancreatic cancer
E. Nasiri, A. Hanlon, V. Lutz, E. Landmann, M. Huber, M. Buchholz, T. Gress
C. Bauer (Marburg)
P 07 Immune regulation properties of sulforaphane in pancreatic cancer
Y. Wang, A. Wieland, E. Petrikova, J. Gladkich, W. Groß, N. Gretz, I. Herr
S. Karakhanova (Heidelberg)
P 09 Glyoxalase-I – A novel target for pancreatic cancer?
M. Hollenbach, J. Lorenz, I. Sommerer, S. Sonnenberg, P. Reichwald
J. Mössner (Leipzig), J. Rosendahl, P. Michl (Halle a. d. Saale)
A. Hoffmeister (Leipzig)
17POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR
POSTER SESSIONS I THURSDAY, 7. FEBRUARY
P 10 An immunohistochemical analysis of heat shock protein 27 in pancreatic
ductal adenocarcinoma
R. Drexler, K.-J. Oldhafer, K.-C. Wagner, M. Küchler (Hamburg)
P 12 The serine/threonine kinase FASTK is overexpressed in pancreatic ductal
adenocarcinoma and its downregulation inhibits growth in 2D and 3D cell
models
M. Tatura, T. Gress, M. Buchholz (Marburg)
P 13 Characterising inflammatory signaling pathways in ARID1a-deficient PDAC
subtypes
L. Aperdannier, E. Hessmann (Göttingen)
15:45–17:15 Poster session 2 I Surgery
Room Terminal 2
Chairs J. G. D’Haese (Munich), U. Wellner (Lübeck)
P 14 Preoperative biliary stenting is associated with higher postoperative
morbidity and equivalent mortality in patients with hyperbilirubinemia:
an analysis of the German DGAV StuDoQlPancreas registry
L. Bolm, E. Petrova, L. Woehrmann (Lübeck), J. Werner (Munich)
W. Uhl (Bochum), N. Nuessler (Munich), M. Ghadimi (Göttingen)
D. Bausch, H. Lapshyn (Lübeck), J. Gaedcke (Göttingen)
O. Belyaev (Bochum), J. G. D‘Haese, T. Klier (Munich), T. Keck
U. Wellner (Lübeck)
P 15 Metastatic renal cell carcinomas target the fatty pancreas
T. Fahlbusch, W. Uhl, C. Braumann (Bochum)
P 16 Natural history and treatment of solid-pseudopapillary tumors of the
pancreas – a population based study of 100 patients and review of the
literature
M. Renz (Nuremberg)
P 17 Human tissue related kallikreins as potential biomarker and prognostic
variable in pancreatic cancer
J. Eberhard (Mannheim), A. Soosaipillai (Toronto/CA)
C. Reissfelder (Mannheim), E. P. Diamandis (Toronto/CA)
F. Rückert (Mannheim)
18POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR
POSTER SESSIONS I THURSDAY, 7. FEBRUARY
P 18 Drainage management in patients receiving pancreatic head resection:
a single center analysis in the wake of the PANDRA trial
E. Rasbach, C. Reissfelder, F. Rückert (Mannheim)
P 19 The presence of special bacteria at the time of surgery seems to increase
the rate of postoperative complications after pancreas surgery
E. A. Biesel, P. Weyhmüller, O. Sick, F. Makowiec, U. Hopt, S. Fichtner-Feigl
U. Wittel (Freiburg)
P 20 Alternative approach using CT-guided percutaneous injection of thrombin
foam in recurrent bleeding into a pseudocyst due to acute pancreatitis and
simultaneous aortic dissectio
C. Wex (Magdeburg), J. Jürgens (Hamburg), J. Schiefer (Magdeburg)
O. Dudeck (Zurich/CH), J. Rabczak, F. Meyer (Magdeburg)
P 21 Prognostic factors of survival in 196 patients undergoing
duodeno-pancreatectomy for distal bile duct cancer
C. Tjaden, U. Klaiber, U. Hinz, O. Strobel, J. Neoptolemos, M. W. Büchler
T. Hackert (Heidelberg)
P 22 Inflammatory myofibroblastic tumor of the pancreas – case report and a
review of the literature
M. Sorleto, S. Elhabash, M. Alnabki, I. Dimopoulus, R. Sekhri, C. Gartung
B. Gerdes (Minden)
P 23 Delayed gastric emptying does not influence cancer specific survival after
pancreatoduodenectomy for pancreatic adenocarcinoma
T. R. Glowka, J. Hafke, S. Manekeller, J. C. Kalff (Bonn)
P 24 Clinical presentation and outcome of adenosquamous carcinoma of the
pancreas – a matched pair analysis to pancreatic ductal adenocarcinoma
J. Kaiser, U. Hinz, T. Hank, W. Niesen, D. Jäger, T. Hackert, M. W. Büchler
O. Strobel (Heidelberg)
P 48 Ezh2 controls PDAC plasticity by regulating differentiation genes
S. Patil, Z. Najafova, V. Kari, B. Steuber, H. Bohnenberger, W. Kopp
A. Neesse, V. Ellenrieder, S. A. Johnsen, E. Hessmann (Göttingen)
19POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR
POSTER SESSIONS I THURSDAY, 7. FEBRUARY
15:45–17:15 Poster session 3 I Inflammation and carcinogenesis
Room Terminal 3
Chairs G. Beyer (Munich), S. K. Singh (Göttingen)
P 26 The role of IL-18 in pancreatic fibrosis
Z. Li, M. Weniger, J. Werner, A. V. Bazhin, J. G. D’Haese (Munich)
P 27 Autoimmune pancreatitis type 1 associated with a pancreatic pseudocyst
F. Hesse, R. Braren, R. Schmid, V. Philipp (Munich)
P 28 Regulation of transcription factors in the ER stress recognition system
during acute pancreatits
R. Bolsmann, F. U. Weiß (Greifswald), J. Mayerle (Munich), M. M. Lerch
M. Sendler (Greifswald)
P 29 IRAK-M regulates local and systemic immune responses in acute
pancreatitis
F. Thiel, F. U. Weiß, M. M. Lerch, M. Sendler (Greifswald)
P 30 An in vitro system to evaluate potential therapeutic substances for ER stress
reduction during pancreatitis
J. M. Modenbach, F. U. Weiß (Greifswald), M. Gronbach, C. Oppermann
F. El-Hage, J. Pospech (Rostock), M. M. Lerch, M. Sendler (Greifswald)
P 31 The influence of receptors for advanced glycation end products (AGE-R´s)
and advanced glycation end products (AGE”s) in patients suffering from
chronic pancreatitis
N. Hesselbarth, R. Böhme, C. Böhme, P. Michl, J. Rosendahl (Halle a. d. Saale)
P 32 Role of receptors for advanced glycation end products in development of
pancreatitis and pancreatic cancer
R. Böhme, N. Hesselbarth, P. Michl, J. Rosendahl (Halle a. d. Saale)
P 33 Betacellulin protective effects against experimental acute pancreatitis are
ERBB4-dependent
K. Hedegger, H. Algül, M. Lesina, M. Schneider, M. Dahlhoff (Munich)
P 34 TLR3 is required for pancreatic regeneration
A. Hidalgo Sastre, L. Jochheim, K. Steiger, R. Schmid, B. Holzmann
G. von Figura (Munich)
20POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR
POSTER SESSIONS I THURSDAY, 7. FEBRUARY
P 35 Efficacy and safety of lumen-apposing metal stents for the drainage of
pancreatic fluid collections in a large retrospective multicenter analysis
S. Zeissig, S. Sulk, S. Brückner, R. Schmelz, J. Babatz, M. Berning, C. Kirsch
S. Pannach, K. Matthes, M. Hohmann (Dresden), S. Reichel (Gera)
M. Ellrichmann, A. Arlt (Kiel), U. Will (Gera), J. Hampe (Dresden)
P 36 Different characteristics of dibutyltin dichloride-induced chronic
pancreatitis and hepatitis in mouse and rat
F. Lütt, H. Nizze, R. Jaster (Rostock)
P 37 Hippo regulates proliferation and matrix protein synthesis of pancreatic
stellate cells
L. Spanehl, R. Jaster (Rostock)
P 38 Intrapancreatic zymogen activation in response to autophagy modulation in
caerulein hyperstimulated mice
T. Wartmann, H. Faber-Zuschratter, F. Meyer (Magdeburg), K. Diakopoulos
H. Algül, J. Mayerle (Munich), M. M. Lerch (Greifswald), W. Halangk
R. Croner (Magdeburg)
www.conventus.de
© Nejron Photo / Fotolia
Success through
versatile
solutions
As a full-service PCO, we provide you with
intelligent and innovative solutions in an advisory
and implementing manner.
21POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR
POSTER SESSIONS I FRIDAY, 8. FEBRUARY
12:30–14:00 Poster session 4 I Molecular mechanisms and novel therapies in PDAC
Room Terminal 1
Chairs M. Sendler (Greifswald), H. Griesmann (Halle a. d. Saale)
P 39 The role of BRD3 in pancreatic ductal adenocarcinoma
A. P. Kutschat, F. Hamdan, Xin. Wang, S. A. Johnsen (Göttingen)
P 40 Cellular immunotherapy for pancreatic cancer – evaluation of novel target
candidates
D. Schäfer (Bergisch Gladbach, Göttingen), L. N. Küster, S. Tomiuk
A. Bosio (Bergisch Gladbach), J. Missbach-Güntner, D. Pinkert-Leetsch
F. Alves (Göttingen), O. Hardt (Bergisch Gladbach)
P 41 Impact of Tlr3 on acinar-to-ductal metaplasia and pancreatic cancer
progression
S. Benitz, L. Fahr, J. Mutter, H. Lisiecki (Munich), J. Kleeff (Halle a. d. Saale)
I. Esposito (Düsseldorf), J. Mayerle (Munich), C. Michalski (Halle a. d. Saale)
I. Regel (Munich)
P 42 Uncovering the role of ERBB receptors in pancreatic ductal adenocarcinoma
upon betacellulin-induced signaling in mice
K. Hedegger, H. Algül, M. Lesina, M. Schneider, M. Dahlhoff (Munich)
P 43 Sulforaphane enhances gemcitabine cytotoxicity in pancreatic cancer
through downregulation of miR-30a-3p
C. Georgikou, L. Yin, J. Gladkich, X. Xiao (Heidelberg), C. Sticht
C. De La Torre (Mannheim), W. Groß (Heidelberg), N. Gretz (Mannheim)
S. Karakhanova, I. Herr (Heidelberg)
P 44 Metabolic profiling and targeting of pancreatic ductal adenocarcinoma
S. Karakaya, A. Winkelkotte, S.-T. Liffers, S. S. Lueong (Heidelberg, Essen)
M. Matzka, M. Aichler, A. Walch (Munich), W. Yang, A. Harms
T. Hankemeier (Leiden/NL), S. Hahn (Bochum) M. Trajkovic-Arsic
J. Siveke (Essen, Heidelberg)
P 45 Generation and development of a novel dual bet/hdac inhibitor with
promising anti-tumor properties
X. Zhang, T. Zegar (Essen), R. Lucas, T. Weiser (Frankfurt)
M. Trajkovic-Arsic (Essen), M. Remke (Düsseldorf), S. Mergener (Essen)
S. Knapp (Frankfurt), J. Siveke (Essen)
22POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR
POSTER SESSIONS I FRIDAY, 8. FEBRUARY
P 46 Characterisation of immune-based mechanisms in pancreatic ductal adeno
carcinoma
C. Neander, M. Trajkovic-Arsic, S.-T. Liffers, P. F.-Y. Cheung, J. Siveke (Essen)
P 47 Combined treatment with cisplatin and HSP90 Inhibitors – towards a
syngeneic orthotopic mouse model of pancreatic cancer therapy
K. M. Ewers, S. Patil, W. Kopp, E. Hessmann, M. Dobbelstein (Göttingen)
P 25 Investigating the role of SMAD7 in PDAC
I. L. Zawallich, Y. Sunami, C. Michalski, J. Kleeff (Halle a. d. Saale)
P 49 Boolean network-based modeling of gene regulatory networks mediating
the growth-promoting role of CFL1 in pancreatic cancer
S. Kühlwein (Ulm), T. Gress (Marburg), H. A. Kestler, M. Buchholz (Ulm)
P 50 sgRNA-transgenic mice enable inducible intra-pancreatic genome editing
and the generation of large homozygous chromosomal deletions in vivo
A. Mishra, K. wolff, Z. Erlangga, M. Manns, A. Vogel, A. Saborowski
M. Saborowski (Hannover)
12:30–14:00 Poster session 5 I Surgery
Room Terminal 2
Chairs F. Rückert (Mannheim), S. Chikhladze (Freiburg)
P 51 Perioperative detection of deeply located pancreatic tumour lesions in mice
using optoacoustic and fluorescence-based imaging
J. Napp (Göttingen), M. A. Stammes (Enschede, Leiden/NL)
J. Claussen (Munich), H. A. J. M. Prevoo, C. F. M. Sier (Gouda/NL)
F. J. M. Hoeben (Eindhoven/NL), M. S. Robillard (Nijmegen/NL)
A. L. Vahrmeijer (Leiden/NL), T. Devling (Munich)
A. B. Chan (Enschede/NL), L.-F. de Geus-Oei (Leiden, Enschede/NL)
F. Alves (Göttingen)
P 52 Accuracy of CA19-9 in detecting recurrence of pancreatic cancer after
curative intended therapy
A. Azizian, F. Rühlmann, T. Krause, M. Bernhardt, P. Jo, A. König (Göttingen)
M. Kleiß (Kassel), X. Schulz, M. Ghadimi, J. Gaedcke (Göttingen)
P 53 Ultrasound imaging – method of choice in early detection of pancreatic
carcinoma
M. Lang, C. Tjaden, T. Hackert (Heidelberg)
23POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR
POSTER SESSIONS I FRIDAY, 8. FEBRUARY
P 54 Randomised controlled trial of pylorus-preserving versus pylorus-resecting
pancreatoduodenectomy (PROPP study) – long-term morbidity and quality
of life
U. Klaiber, P. Probst, F. J. Hüttner, O. Strobel, M. K. Diener, A. L. Mihaljevic
M. W. Büchler, T. Hackert (Heidelberg)
P 55 Evaluation of postoperative quality of life after pancreatic surgery and its
influencing factors
S. Manschikow, S. Deichmann, U. Wellner, K. C. Honselmann, L. Bolm
L. Frohneberg, T. Keck, D. Bausch (Lübeck)
P 56 Damage control at abdominal trauma – pancreatic injuries
M. Putzbach, S. Fabig, N. Weigert, J. Kleeff (Halle a. d. Saale)
P 57 Vein resection during pancreatectomy for pancreatic cancer:
a meta-analysis
Xia. Wang, I. E. Demir, S. Schorn, H. Friess, G. O. Ceyhan (Munich)
P 58 Bacterobilia does not influence delayed gastric emptying following
pancreatoduodenectomy
J. Hafke, S. Manekeller, J. C. Kalff, T. R. Glowka (Bonn)
P 59 Incidence and management of surgical revision requiring pancreatic fistulas
grade C after pancreaticoduodenectomy – a retrospective analysis of 722
patients
A. M. Luu, T. Herzog, L. Krasemann, W. Uhl, C. Braumann (Bochum)
P 60 Effects of standardised plant extracts of the japanese Kampo medicine on
human and murine pancreatic cancer cells
K. Weimer, L. Frank (Göttingen), H. Rausch (Neu-Ulm), V. Ellenrieder
S. Cameron (Göttingen)
P 61 Incidence and treatment of portal vein thromboses after portal vein
resections in pancreatic surgery
M. Weniger (Munich), Z. Lu (Nanjing/CN), A. Doll (Munich)
Y. Miao (Nanjing/CN), J. Werner, J. G. D’Haese (Munich)
P 62 Expression of EWS/FLI-1 oncogene in pancreatic acinar cells induces
adipo-cyte replacement
Y. Sunami (Halle a. d. Saale), I. Regel, B. Kong, S. Raulefs (Munich)
C. Michalski, J. Kleeff (Halle a. d. Saale)
24POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR
POSTER SESSIONS I FRIDAY, 8. FEBRUARY
12:30–14:00 Poster session 6 I Tumor microenvironment
Terminal 3
Chairs D. Ruess (Freiburg), K. C. Honselmann (Lübeck)
P 63 Tumor-subtype dependent transcriptional regulation in pancreatic cancer
plasticity and resistance
M. Tu, S. Önder, J. M. Güntner, V. Ellenrieder, S. K. Singh (Göttingen)
P 64 Exploiting tumor-stroma hedgehog signal transduction heterogeneity
R. Singh (Marburg)
P 65 Anterior gradient 2 promotes the phenotypic transition from ADM to PanIN
by suppressing p53 function
Z. Zhang, L. Chang, S. Raulefs, N. Maeritz, Ya. Zhao, G. O. Ceyhan
H. Friess (Munich), C. Michalski, J. Kleeff (Halle a. d. Saale)
B. Kong (Munich)
P 66 NFkB2 Signaling is modulated by oncogenic context in the Carcinogenesis in
the Pancreas
Z. Hassan, C. Schneeweis, M. Wirth, S. Müller, R. Rad, D. Saur, R. Schmid
G. Schneider (Munich)
P 67 Dexamethasone mediates pancreatic cancer progression by glucocorticoid
receptor, TGFb and JNK/AP-1
L. Liu, E. Aleksandrowicz, F. Schönsiegel, N. Bauer, C. C. Nwaeburu, Z. Zhao
J. Gladkich, W. Groß, T. Hoppe-Tichy, O. Strobel, I. Herr (Heidelberg)
P 68 Comprehensive molecular characterisation of a pancreatic cancer PDX
cohort for subtype-specific therapy approaches
S.-T. Liffers, S. S. Lueong, S. Mergener, J. Forster (Essen)H. Wolters (Dortmund)
R. Viebahn, A. Tannapfel, W. Uhl, S. Hahn (Bochum), J. Siveke (Essen)
P 69 Functional characterisation of the Ubiquitin-Proteasome-System in
pancreatic ductal adenocarcinoma
F. Lang, S. S. Lueong (Essen), O. Karpiuk, F. Bassermann (Munich)
J. Siveke (Essen)
P 70 STAT3 signaling determines the oncogenic function of NFATc1 in pancreatic
cancer plasticity and resistance
L. Klein, S. Önder, V. Ellenrieder, S. K. Singh (Göttingen)
25POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR
POSTER SESSIONS I FRIDAY, 8. FEBRUARY
P 71 uPAR knock out induces mesenchymal-epithelial transition (MET) and
chemoresistance in AsPC1 cells
L. Peng, S. Küffer, V. Venkataramani, J. Kitz, M.-S. Bösherz
H. Bohnenberger, F. Fuchs, S. Hakroush, P. Ströbel (Göttingen)
P 72 DeltaNp63-dependent super enhancers define molecular identity in
pancreatic cancer by an interconnected transcription factor network
F. Hamdan, S. A. Johnsen (Göttingen)
P 73 Growth inhibitory effects of inhibition of PLAC8 expression in exocrine
(PDAC) and neuroendocrine (panNET) tumors of the pancreas is associated
with deregulation of a miR-26a-E2F2 axis
M. Stark, M. Tatura, A. Kuhl, T. Gress, M. Buchholz (Marburg)
P 74 Selective inhibition of sphingolipids metabolism in macrophages using acid
sphingomyelinase inhibitor-coupled IL4 receptor specific aptamers
Qi. Li, J. Peterhansl, I. Regel, U. M. Mahajan, J. Mayerle (Munich)
P 75 Oncogenic NFATc1-activity promotes cancer cachexia in murine
PDAC-models
D. Spyropoulou, E. Hessmann, H. Bohnenberger, D. Saul (Göttingen)
26Abend- und Rahmenprogramm
Begrüßungsabend im Deutschen Theaterkeller
Donnerstag, 7. Februar
Mitten im Herzen Göttingens, direkt am Wall, liegt
eines der wohl beliebtesten Fotomotive der Stadt:
das Deutsche Theater Göttingen.
Wir laden Sie recht herzlich zum Begrüßungs-
abend in das Bistro ein und freuen uns, mit Ihnen
gemeinsam einen gemütlichen Abend bei kleinen
Snacks und Getränken zu verbringen.
BildPix.de l Fotolia.com
Adresse Deutsches Theater Keller + Bistro
Theaterplatz 11
Beginn 19:30 Uhr
Kosten kostenfrei, eine Anmeldung ist jedoch erforderlich, da die Plätze begrenzt sind
Wegbeschreibung
Das Deutsches Theater in Göttingen liegt nur 6 Gehminuten von der Alten Mensa Göttingen
entfernt.
Gehen Sie auf dem Wilhelmsplatz nach Osten und biegen Sie links auf der Burgstraße ab. Nach
ca. 100 Metern biegen Sie linkerhand auf die Theaterstraße ab und nach weiteren 200 Metern
biegen Sie links ab auf den Theaterplatz, wo Sie das Ziel erreicht haben.
Gesellschaftsabend in der Orangerie im Freizeit In Hotel
Freitag, 8. Februar
Lassen Sie die bisherigen Kongresserlebnisse Revue passieren. Zum Ausklang des zweiten
Tages laden wir Sie herzlich in die Orangerie des Hotels Freizeit In ein.
Genießen Sie einen unterhaltsamen Abend mit gutem Essen, Musik der Band „Ladies Live“
und Tanz sowie interessanten Gesprächen mit Freunden und Kollegen.
Adresse Hotel Freizeit In GmbH
Dransfelder Straße 3
Beginn 20:00 Uhr
Kosten 45 EUR, eine Anmeldung ist erforderlich, da die Plätze begrenzt sind
Wegbeschreibung
Nur drei Gehminuten von der Alten Mensa Göttingen entfernt nutzen Sie die Buslinie 61
(Haltestelle „Jüdenstraße“) in Richtung Dransfeld zur Haltestelle „Dransfelder Straße“. Diese
liegt dem Hotel Freizeit In direkt gegenüber.
27INDUSTRIEGESTÜTZE SESSIONS
10:15–12:00 Session 4 I Satellite Symposium supported by Celgene
Clinical trials and novel therapies
Room Adam-von-Trott-Saal
Chairs V. Ellenrieder (Göttingen), C. Bruns (Cologne)
10:15 Keynote I Immuno-Oncology – the basics and future perspectives
H. Flach (Munich)
10:45 In-depth molecular characterisation of pancreatic ductal adenocarcinoma
based on patient-derived tumor organoids
S. Le Blanc, T. Bauer (Heidelberg), N. Ishaque (Berlin), S. Schuth, A.-K. König
M. Volkmar, C.-S. Leonhardt, J. Jabs, U. Toprak, M. Schenk, N. Giese
R. Offringa, C. Conrad, M. W. Büchler, M. Schlesner (Heidelberg)
R. Eils (Heidelberg, Berlin), O. Strobel (Heidelberg)
10:53 Keynote I Future clinical trial concepts in PDAC
J. Siveke (Essen)
11:23 Reliability of determining the resectability of locally progressed pancreatic
ductaladenocarcinomas – results from the CONKO-007 multicenter
randomised controlled trial (EudraCT:2009-014476-21)
U. Wittel (Freiburg), H. Golcher, R. Grützmann (Erlangen)
W. Bechstein (Frankfurt), O. Belyaev, W. Uhl (Bochum)
M. Ghadimi (Göttingen), U. Hopt (Freiburg), A. Pirkl, D. Lubgan
W. Hohenberger (Erlangen), H. Oettle (Friedrichshafen)
R. Fietkau (Erlangen)
11:31 Comparative characterisation and epigenetic/metabolic targeting of
primary 2D and 3D cultured PDAC cells
S.-T. Liffers, S. Mergener, A. Winkelkotte, M. Trajkovic-Arsic, S. S. Lueong
J. Forster (Essen), S. Hahn (Bochum), J. Siveke (Essen)
11:39 Keynote I PASS1/2 trial
J. Neoptolemos (Heidelberg)
2829
o to lia.c o m
i nte r may a l f
s p l ay
© diINDUSTRIEGESTÜTZE SESSIONS
17:15–18:30 Session 7 I Satellite Symposium supported by Akcea
Acute and chronic pancreatitis
Room Adam-von-Trott-Saal
Chairs J. Rosendahl (Halle a. d. Saale), J. Mayerle (Munich)
17:15 Myeloid derived suppressor cell (MDSCs) differentiation during acute
pancreatitis regulates the systemic immune response
A. Wilden, J. Glaubitz, J. Golchert, G. Homuth, F. U. Weiß (Greifswald)
J. Mayerle (Munich), M. Sendler, M. M. Lerch (Greifswald)
17:23 Mast cell stabilisers ameliorate pain in experimental chronic pancreatitis
S. Klauss, S. Schorn, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich)
17:31 Keynote I Pancreatitis in patients with lipid disorders
M. M. Lerch (Greifswald)
18:01 Gender-dependent mechanisms of autophagy in the transition of acute to
chronic pancreatitis
K. Diakopoulos, A. Berninger, M. Kowalska, K. Görgülü, M. Lesina, J. Ai
A.-F. Karpathaki, D. Kabacaoglu, K. J. Ciecielski, E. Kaya-Aksoy, R. Schmid
H. Algül (Munich)
18:09 Pancreatic autophagy attenuates endotoxin-induced pancreatic injury
L. Xia, T. Hackert, F. Fortunato (Heidelberg)
18:17 Absence of LMP7 immunoproteasome subunit leads to delayed organ
recovery after acute pancreatitis
L. De Freitas Chama, F. U. Weiß, F. Ebstein, E. Krüger, M. M. Lerch
M. Sendler (Greifswald)
30Connecting and Advancing
Health Sciences
The Interdisciplinary Approach to
Gastrointestinal Medicine
VISCERAL MEDICINE is your one-stop source for essential knowledge Visceral
Breast Care
needed to master the major interdisciplinary challenges in gastro- Medicine
intestinal medicine and surgery. Each issue focuses on one selec-
Gastroenterology, Endoscopy and Surgery –
The Interdisciplinary Approach to Gastrointestinal Disease
ted topic, and the invited reviews provide a comprehensive, state-
of-the-art background in clinical practice and research. A panel of
specialists in gastroenterology, surgery, radiology, and pathology
discusses different approaches to diagnosis and treatment of the
featured topic. Original articles, case reports, and commentaries S. Karger
Medical and Scientific Publishers
Basel · Freiburg · Paris · London · Associated Organ
New York · Chennai · New Delhi · for Continuing Education
add additional valuable insights.
Bangkok · Beijing · Shanghai ·
Tokyo · Kuala Lumpur ·
Singapore · Sydney
www.karger.com/vis
In cooperation with DGAV
(Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie)
More than 40 Years of Excellence
For over 40 years, ONCOLOGY RESEARCH AND TREATMENT has been an inter-
disciplinary forum for cancer research and treatment. Peer-reviewed
original and review articles cover a wide range of topics and aspects
in medical and hemato-oncology. Focus issues select one specific
cutting-edge topic and expand on its various facets in the form of
mini reviews. Compact and current, ONCOLOGY RESEARCH AND TREATMENT
keeps both clinicians and researchers up-to-date.
Österreichische Gesellschaft für
Hämatologie & Medizinische Onkologie
Österreichische Gesellschaft für
Hämatologie & Medizinische Onkologie
www.karger.com/ort
Official DGHO – Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
Organ of ÖGHO – Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie
DFaG – Deutsche Fatigue Gesellschaft
AIO – Arbeitsgemeinschaft Internistische Onkologie in der deutschen Krebsgesellschaft e.V.
SGH-SSH – Schweizerische Gesellschaft für Hämatologie
Member of Deutsche Krebsgesellschaft e.V.
S. Karger Verlag für Medizin und Naturwissenschaften GmbH
Wilhelmstraße 20A t +49 761 45207- 0
79098 Freiburg f +49 761 45207- 14
www.karger.com information@karger.com
31SPONSOREN UND MEDIENKOOPERATION Ein großes Dankeschön gilt allen Partnern für ihre Unterstützung und kooperative Zusammenarbeit: Premiumsponsoren Akcea Therapeutics Celgene GmbH Silbersponsoren SERVIER Deutschland GmbH Bronzesponsoren Bristol-Myers Squibb GmbH & Co. KGaA GE Healthcare GmbH Johnson & Johnson Medical GmbH - Ethicon Ipsen Pharma GmbH Weitere Sponsoren Boston Scientific Halozyme, Inc. Lilly Deutschland GmbH MTW-Endoskopie W. Haag KG Peter Pflugbeil GmbH Medienkooperation S. Karger GmbH „Karger Kompass Onkologie“ „Oncology Research and Treatment“ „Visceral Medicine“ Stand bei Drucklegung 32
Successful patient management
requires a lot more than one move.
AXIOS™
Stent and Electrocautery Enhanced Delivery System
Bringing the patient care pieces together.
The AXIOS Stent and Delivery System is indicated for use to facilitate
transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst
or a walled-off necrosis with ≥ 70% fluid content or the biliary tract.
All trademarks are the property of their respective owners.
Caution: The law restricts this device to sale by or on the order of a physician.
Product available in the European Economic Area (EEA) only. Please check availability
with your local sales representative or customer service.
Indications, Contraindications, Warnings and Instructions for Use can be found in the
product labeling supplied with each device.
Contact your local sales representative or visit 33
2016 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved.
www.bostonscientifi c.eu/gastroenterology. ENDO-426401-AAAUSSTELLER
Aussteller Standnummer
Arbeitskreis der Pankreatektomierten e. V. 9
Akcea Therapeutics 5
BAXTER Deutschland GmbH 12
Bracco Imaging Deutschland GmbH 18
Bristol-Myers Squibb 16
Celgene GmbH 7
Dr. Falk Pharma GmbH 2
Ewimed 11
GE Healthcare GmbH 8
IntraOp 14
Ipsen Pharma GmbH 4
Johnson & Johnson 19
Liquid Biopsy GmbH 21
LISA Laser Products GmbH 1
Meda Pharma 20
Medi-Globe GmbH 10
Medtronic 15
Nordmark Arzneimittel GmbH & Co. KG 6
Novartis Pharma GmbH 13
Roche Pharma AG 17
Servier Deutschland GmbH 3
Stand bei Drucklegung
34RAUM- UND AUSSTELLERPLAN
16 3
1
5 11 15 21
2
10 14
20
2 9 13
19
8 12
4 18
7
17
3
zum
Vortragssaal
6
g
an
ng
i
te
up
Ha
ePoster Sta on
1 Catering
Check-In
Stand bei Drucklegung
35ALLGEMEINE INFORMATIONEN
Allgemeine Geschäftsbedingungen
Die Allgemeinen Geschäftsbedingungen entnehmen Sie bitte der Tagungs-
AGB
homepage.
Anwesenheitslisten und Teilnahmezertifikate
Für die Zertifizierung werden die Teilnehmer gebeten, sich täglich mit ihrem
EFN-Barcode am Check-In einzuscannen. Dort erhalten Sie auch die Teilneh-
merzertifikate.
Catering
Getränke und Snacks werden den Teilnehmern kostenfrei während der
Pausen angeboten.
Kongresssprache
Die Vorträge sowie Posterpräsentationen werden auf Englisch gehalten.
Posterausstellung
Alle Poster können während der gesamten Tagung sowohl an den ePoster-
Terminals als auch an kleinen Bildschirmen zum Selbststudium eingesehen
werden.
Vortragsannahme
Bitte geben Sie Ihren Vortrag direkt im Hörsaal ab.
Wissenschaftliche Preise
Die Preisverleihungen finden während des Gesellschaftsabends am Freitag
statt. Die besten Abstracteinreichungen sind im Programm mit einem Pokal
gekennzeichnet.
Zertifizierung und Fortbildungspunkte
Die 39. Jahrestagung des Deutschen Pankreasclub e. V. wurde von der Ärzte-
kammer Niedersachsen mit folgenden Punkten zertifiziert:
Donnerstag 3 Punkte
Freitag 6 Punkte
Samstag 3 Punkte
36Index Referenten, Autoren und Vorsitzende
A
Abdelhafez, M. 12 Berninger, A. 13, 30
Acciuffi, S. 7, 9 Bertucci, F. 12
Ai, J. 13, 30 Beyer, G. 20
Aichler, M. 22 Biesel, E. A. 19
Akkan, J. 8, 16 Birgin, E. 17
Aleksandrowicz, E. 25 Birnbaum, Dan. 12
Algül, H. 7, 13, 20, 21, 22, 30 Birnbaum, Dav. 12
Alhamdani, M. S. S. 15 Böhme, C. 20
Alnabki, M. 19 Böhme, R. 20
Alves, F. 22, 23 Bohnenberger, H. 16, 19, 26
Aperdannier, L. 16, 18 Böker, V. 15
Appel, L. 15 Bolm, L. 9, 11, 18, 24
Arlt, A. 6, 11, 21 Bolsmann, R. 20
Arnold, F. 7 Bösherz, M.-S. 26
Aselmann, H. 11 Bosio, A. 22
Augustin, L. 12 Bourquain, U. 17
Azizian, A. 23 Braren, R. 12, 20
Braumann, C. 18, 24
B Breitling, L. P. 14
Babatz, J. 21 Breunig, M. 8, 16
Bahra, M. 11 Bronsert, P. 14
Bassermann, F. 25 Brooks, J. 9
Bauer, A. S. 15 Brückner, S. 11, 21
Bauer, C. 17 Bruns, C. 10, 12, 28
Bauer, N. 25 Buchholz, M. 17, 18, 23, 26
Bauer, T. 10, 28 Buchler, M. 9
Baum, R. P. 14 Büchler, M. W. 7, 9, 10, 15, 19, 24, 28
Baumann, D. 12 Büchter, M. 8
Bausch, D. 9, 11, 16, 18, 24 Busch, C. 11
Bazhin, A. V. 7, 17, 20
Bechstein, W. 10, 28 C
Becker, T. 11 Cameron, S. 24
Begg, S. 12 Cao, J. 8, 16
Belyaev, O. 10, 18, 28 Ceyhan, G. O. 8, 9, 12, 13, 15, 16, 17, 24
Benitz, S. 8, 16, 22 25, 30
Bergmann, F. 14 Chan, A. B. 23
Bernhardt, M. 23 Chang, L. 16, 25
Berning, M. 21 Cheung, P. F.-Y. 23
37Index Referenten, Autoren und Vorsitzende
Chikhladze, S. 23 Ellenrieder, V. 8, 10, 12, 15, 19, 24, 25, 28
Ciecielski, K. J. 13, 30 Ellrichmann, M. 11, 21
Claussen, J. 23 Engleitner, T. 12
Conrad, C. 10, 17, 28 Erlangga, Z. 23
Croner, R. 7, 9, 21 Esposito, I. 16, 22
Ewers, K. M. 23
D
D’Haese, J. G. 7, 16, 20, 24 F
Dahlhoff, M. 20, 22 Faber-Zuschratter, H. 21
Dantes, Z. 12 Fabig, S. 24
De Freitas Chama, L. 13, 30 Fahlbusch, T. 18
de Geus-Oei, L.-F. 23 Fahr, L. 8, 22
De La Torre, C. 22 Feldmann, K. 12
Deichmann, S. 11, 24 Felix, K. 14
Demir, I. E. 7, 9, 13, 15, 17, 24, 30 Fernandez-del Castillo, C. 12
Devling, T. 23 Fichtner-Feigl, S. 19
D‘Haese, J. G. 7, 8, 16, 17, 18, 20, 24 Fietkau, R. 10, 28
Diakopoulos, K. 13, 21, 30 Finetti, P. 12
Diamandis, E. P. 18 Flach, H. 10, 28
Diener, M. K. 24 Flossdorf, M. 15
Dimopoulus, I. 19 Forster, J. 10, 25, 28
Dinh, B. B. K. 16 Fortunato, F. 13, 30
Distler, M. 9, 11 Frank, L. 24
Dobbelstein, M. 23 Frappart, P.-O. 7, 16
Doll, A. 24 Friess, H. 8, 9, 12, 13, 15, 16, 17, 24, 25, 30
Dralle, H. 9 Frohneberg, L. 11, 24
Drebant, J. 12 Fuchs, F. 26
Drewes, R. 7 Füldner, F. 11
Drexler, R. 18
Dudeck, O. 19 G
Gaedcke, J. 6, 9, 18, 23
E Gartung, C. 19
Eberhard, J. 18 Gastinger, I. 9
Ebstein, F. 13, 30 Georgikou, C. 22
Eils, R. 10, 28 Gerdes, B. 19
Eiseler, T. 12 Gerken, G. 8
Elhabash, S. 19 Ghadimi, M. 10, 12, 18, 23, 28
El-Hage, F. 20 Ghaneh, P. 9
38Sie können auch lesen
